Tomorrow we have a session that is shared between the EAN and the PNS, so Peripheral Nerve Society. Basically, we were asked to find the most impactful publication during the year 2025 on peripheral nerve diseases. And basically, we are going to talk about new treatments. So there is a new treatment now for ATTR with polyneuropathy. So I’m going to talk about that, and also a new biomarker for diabetic neuropathy...
Tomorrow we have a session that is shared between the EAN and the PNS, so Peripheral Nerve Society. Basically, we were asked to find the most impactful publication during the year 2025 on peripheral nerve diseases. And basically, we are going to talk about new treatments. So there is a new treatment now for ATTR with polyneuropathy. So I’m going to talk about that, and also a new biomarker for diabetic neuropathy. And finally, AI helping clinicians in the EMG work to basically improve their clinical findings of their tests and improving also the reports, so it’s more accessible to other neurologists to understand what has been found during the test.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
